Volociximab  (Synonyms: M200; Eos 200-4)

Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC₅₀=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs)^[1][2].

Human IgG4 kappa

Human IgG4 kappa, Isotype Control

Chimeric

Volociximab (20, 40, 80, 160, 320 nM) 特异性靶向整合素 α5β1 (K_d=0.367 nM)，而不是整合素 α5α5 或 β1β1^[1]。
Volociximab (0.01-100 nM; 4 d) 抑制人脐静脉血管内皮细胞 (HUVEC) 增殖 (IC₅₀=0.2-0.5 nM)，并 (10 μg/mL; 16 h) 诱导分裂的而非衰老的 HUVEC 的凋亡^[1]。
Volociximab (0.067-67 nM; 6 d) 抑制 0.1 μg/mL VEGF 和/或 bFGF 诱导的 HUVEC 体外血管形成^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Volociximab (300 μg/单眼; 玻璃体注射; 每周 1 次, 共 4 周) 在食蟹猴中耐受性良好，并抑制食蟹猴模型中激光诱导脉络膜新生血管 (CNV) 的血管生成^[1]。 Volociximab (10 mg/kg; 静脉注射; 每周 2 次, 共 3 周) 在兔子 VX2 癌模型中抑制肿瘤进展^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

145.5 kDa (Average)

558480-40-3

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Bhaskar V, et al. Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits. Invest New Drugs. 2008 Feb;26(1):7-12.  [Content Brief]

  [2]. Ramakrishnan V, et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86.  [Content Brief]